The economics of infection

Ebola is a truly frightening disease, with a fatality rate as high as 95 per cent (although the death rate in the current outbreak in West Africa is only 55 to 60 per cent). At the moment, it is largely confined to a heavily forested inland area where the borders of Liberia, Sierra Leone and Guinea meet, although cases have already appeared in the capital cities of all three countries.

Ebola is a truly frightening disease, with a fatality rate as high as 95 per cent (although the death rate in the current outbreak in West Africa is only 55 to 60 per cent). At the moment, it is largely confined to a heavily forested inland area where the borders of Liberia, Sierra Leone and Guinea meet, although cases have already appeared in the capital cities of all three countries.

It could get much worse. If ebola successfully made the jump to a more prosperous, densely populated country like Nigeria, whose citizens travel all over the world, the current 800 recorded deaths could become 8,000, or 80,000, or even more. And the worst of it is that there is no effective vaccine or treatment for ebola.

Let me rephrase that. There is no approved vaccine or treatment for ebola. There are candidates, some of which have shown promising results when tested on non-human primates. But they haven’t gone through the full testing process that is necessary before they are approved for human use, because nobody was willing to pay for it.

The normal procedure in the United States, home to more than half of the world’s major drug companies (“Big Pharma”), is that basic research for new drugs may be paid for by government grants or even by private philanthropy (like Bill Gates’s $200-million donation for research on a malaria vaccine), but the work of bringing the drugs to market is left to the commercial companies. All too often, they simply can’t be bothered.

It costs hundred of millions of dollars to take a drug through the whole approval process and put it on the market. That’s worthwhile if the drug will then sell at a high cost and be used regularly over long periods of time: a drug that fights “rich people’s diseases” like cancer or heart disease, say, or even something like Viagra.

But a one-shot vaccine that would mainly be used by poor Africans will never make a profit, so it is ignored.

Galvanized by the panic over ebola, the National Institutes of Health in the United States has now scheduled phase one trials of an ebola vaccine on human subjects for next month. But there are two more phases after that, and the earliest a vaccine could be approved for general use is next July.

And even in this emergency, it’s public money, not Big Pharma, that is funding the research.

The problem goes much wider than ebola and other tropical diseases. It extends, unfortunately, to the antibiotics that vanquished the bacterial infections that were once responsible for about 25 per cent of adult deaths. The last new class of antibiotics, carbapenems, was approved in 1980. Since then, nothing — even though the usefulness of existing antibiotics is rapidly eroding as resistant strains of bacteria emerge.

That’s a big threat, but antibiotics are still not big money-makers, as they are used for relatively short periods of time to fight some specific infection. So no new type of antibiotic has been developed by Big Pharma for more than three decades.

A minimum of 23,000 people in the United States died last year of infections that would once have been easily ended by antibiotics; in the European Union the total was 25,000.

There are some measures that would dramatically slow the spread of antibiotic-resistant bacteria. Far fewer prescriptions should be written for antibiotics, and doctors should be monitored to ensure that they are not over-prescribing.

Patients must complete any course of antibiotics that they begin, and report that they have done so. Over-the-counter sales of antibiotics in countries like China and Russia must cease.

Above all, it should be a criminal offence to feed antibiotics to animals just to make them grow faster and bigger. (That is where 80 per cent of the antibiotics consumed in the United States go at the moment.) And even when all that has been done, the rise of antibiotic-resistant bacteria will continue, though at a much slower pace. Bacterial resistance is an evolutionary process that can only be slowed, not stopped.

So we desperately need new antibiotics, and there are none forthcoming.

Without them, warned Dame Sally Davies, chief medical officer for England, “Modern medicine would quickly go out of the window.”

Almost all surgery, including things as commonplace as caesarian sections and hip replacements, and most cancer treatments as well, involve a significant risk of infection that must be controlled by antibiotics.

As British Prime Minister David Cameron told The Times: “If we fail to act … we are cast back into the dark ages of medicine, where treatable infections and injuries will kill once again.”

Yet Big Pharma will not fill the gap, for those companies are answerable to their shareholders, not to the public.

The case for direct state intervention to finance the development of the vaccines and antibiotics that the commercial sector neglects is overwhelming. And very urgent.

Gwynne Dyer is an independent journalist whose articles on world affairs are published in 45 countries. His new book, Canada in the Great Power Game 1914-2014, was published by Random House Canada on Aug. 4.

Just Posted

BILD says not the time for higher permit fees in Red Deer

Construction industry is hard hit by slow economy

Bighorn Country telephone town hall for Red Deer area set for Wednesday

Residents can phone in from 6:30-7:30 p.m. to hear about the project or ask questions

Central Alberta real estate sales follow a familiar pattern

2018 house sale numbers mirror 2017 in central Alberta

Red Deer hospital settles dispute, welcomes neonatal nurse

A dispute over nursing levels at Red Deer Regional Hospital Centre’s emergency… Continue reading

Drumheller-Stettler MLA quits UCP

Rick Strankman to sit as Independent

Lucic, Kassian each score twice to power Oilers in 7-2 win over Sabres

EDMONTON — Milan Lucic and Zack Kassian each scored a pair of… Continue reading

Big Valley family gives back to community

Donates $24,560 to Stettler Health Foundation and Edmonton Stollery Children’s Hospital

Giordano notches three points to lead Flames in 7-1 blowout of Coyotes

CALGARY — Flames captain Mark Giordano celebrated his 800th NHL game in… Continue reading

All-female team out to prove women racers aren’t a gimmick

DAYTONA BEACH, Fla. — Every racing series in the world is full… Continue reading

‘Game of Thrones’ final season to debut on April 14

NEW YORK — “Game of Thrones” fans, get ready. HBO announced Sunday… Continue reading

Kylie Jenner loses record for most-liked Instagram post

NEW YORK — Kylie Jenner’s birth announcement is no longer the most-liked… Continue reading

Study shows black bears need a variety of salmon species to be healthy

VANCOUVER — Black bears need access to different species of salmon rather… Continue reading

Trade war’s wounded: Companies improvise to dodge cost hikes

WASHINGTON — In Rochester, New York, a maker of furnaces for semiconductor… Continue reading

Most Read